RxSight, Inc. reported its financial results for the third quarter of 2025, revealing a decline in sales and an increase in net losses compared to the same period last year. The company generated $30.3 million in revenue for the three months ended September 30, 2025, a decrease of 14.1% from $35.3 million in the same quarter of 2024. For the nine months ended September 30, 2025, total sales increased slightly to $101.9 million, up 2.2% from $99.7 million in the prior year. The net loss for the quarter was $9.8 million, compared to a loss of $6.3 million in the third quarter of 2024, while the nine-month net loss rose to $29.8 million from $21.5 million.
The decrease in quarterly sales was primarily attributed to a significant drop in Light Delivery Device (LDD) sales, which fell by 68% year-over-year, from 78 units sold in Q3 2024 to just 25 units in Q3 2025. This decline was partially offset by a 6% increase in Light Adjustable Lens (LAL) sales, which rose by 1,491 units. The company noted that the reduced adoption of its technology among practices and doctors contributed to the lower demand for LDDs. In contrast, the nine-month period saw a 27% increase in LAL sales, driven by a larger installed base of LDDs.
Operating expenses for the third quarter increased to $36.4 million, up 5.7% from $34.4 million in the prior year, with selling, general, and administrative expenses rising by 6.8% to $27.3 million. Research and development expenses also saw a slight increase of 2.5% to $9.1 million. The company attributed the rise in operating expenses to higher selling and marketing costs, as well as increased stock-based compensation.
As of September 30, 2025, RxSight reported cash, cash equivalents, and short-term investments totaling $227.5 million, a decrease from $237.2 million at the end of 2024. The company has indicated that it believes its existing resources will be sufficient to fund operations for at least the next 12 months, although it may seek additional capital to support growth initiatives. RxSight plans to continue investing in its sales and marketing efforts, as well as research and development, to enhance its product offerings and expand its market presence.
Looking ahead, RxSight aims to increase the adoption of its LAL technology and expand its installed base of LDDs, both domestically and internationally. The company is focused on enhancing its product offerings and improving customer experience through a newly integrated Customer Success Organization. Despite the challenges faced in the current market, RxSight remains optimistic about its growth potential and the opportunity to capture a larger share of the premium intraocular lens market.
About RxSight, Inc.
RxSight, Inc. develops innovative ophthalmic solutions, notably the Light Adjustable Lens system, to enhance post-cataract surgery visual outcomes. Its proprietary technology allows surgeons to customize and optimize vision after implantation, addressing limitations of fixed-premium intraocular lenses. Serving ophthalmologists and patients worldwide, the company focuses on improving clinical results, patient satisfaction, and practice growth through advanced, adjustable lens technology.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.